<生产厂家价格>

缓激肽1-5

缓激肽1-5用途

Bradykinin (1-5) 是 Bradykinin 的主要稳定代谢物,由血管紧张素转换酶 (ACE) 经蛋白水解作用形成。

缓激肽1-5名称

[ CAS 号 ]:
23815-89-6

[ 中文名 ]:
缓激肽1-5

[ 英文名 ]:
Bradykinin Fragment 1-5

[英文别名 ]:

Arg-pro-pro-gly-phe
Bradykinin Fragment-1-5
Bradykinin: 1-5
Bradykinin (1-5)

缓激肽1-5生物活性

[ 描述 ]:

Bradykinin (1-5) 是 Bradykinin 的主要稳定代谢物,由血管紧张素转换酶 (ACE) 经蛋白水解作用形成。

[ 相关类别 ]:

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 缓激肽受体

多肽产品

研究领域 >> 心血管疾病

[体内研究]

缓激肽是一种短寿命的血管活性肽,据报道体内半衰期为17秒,在循环中迅速代谢为缓激肽(1-5)。缓激肽(1-5)是ACE在Pro7-Phe8和Phe5-Ser6bonds上连续两次切割缓激肽的产物,已被确定为人体受试者体内缓激肽的主要稳定代谢产物,其终末半衰期为分钟。缓激肽和缓激肽(1-5)均抑制α-和γ-凝血酶诱导的血小板聚集(与基线相比P <0.01)。缓激肽(1-5)以183±3pmol/min的计算剂量抑制γ-凝血酶诱导的血小板聚集50％。缓激肽和缓激肽(1-5)均不影响凝血酶受体激活肽诱导的血小板聚集,这与缓激肽和缓激肽1-5通过阻止凝血酶受体的裂解和凝血酶受体的释放来抑制凝血酶诱导的血小板聚集的假设一致。激活肽。缓激肽(1-5)显着减弱α-凝血酶诱导的血小板聚集,但不显着减弱TRAP 1-6诱导的血小板聚集。缓激肽(1-5)有效抑制γ-凝血酶(500 nM)诱导的血小板聚集,ED50为183±2 pmol/min [1]。

[参考文献]

[1]. Murphey LJ, et al. Bradykinin and its metabolite Bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans. J Pharmacol Exp Ther. 2006 Sep;318(3):1287-92.

[相关活性小分子]

艾替班特 | 缓激肽 | SSR240612 | ELN-441958 | 血管舒缓激肽片段1-8,醋酸盐水合物 | 缓激肽(1-3) | 缓激肽1-6 | 舒缓激肽片段1-7 | 舒缓激肽片段2-9 | FR167344自由基

缓激肽1-5物理化学性质

[ 密度 ]:
1.46g/cm3

[ 分子式 ]:
C₂₇H₄₀N₈O₆

[ 分子量 ]:
572.65600

[ 精确质量 ]:
572.30700

[ PSA ]:
224.04000

[ LogP ]:
1.03610

[ 折射率 ]:
1.677

[ 储存条件 ]:
-20°C

缓激肽1-5MSDS

详细MSDS(安全技术说明书)

缓激肽1-5安全信息

[ 个人防护装备 ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ 危害码 (欧洲) ]:
F+

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
3.0

缓激肽1-5文献

Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass.

Clin. Pharmacol. Ther. 76(4) , 379-87, (2004)

This study tested the hypothesis that angiotensin-converting enzyme (ACE) inhibitors potentiate activation of the kallikrein-kinin system during cardiopulmonary bypass (CPB).The effects of CPB on conc...

Thrombostatin inhibits cyclic flow variations in stenosed canine coronary arteries.

Thromb. Haemost. 86(5) , 1296-304, (2001)

Thrombostatins are a group of compounds based upon a breakdown product of bradykinin, RPPGF. They inhibit alpha-thrombin-induced platelet activation by binding to protease activated receptor 1 and, at...

Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.

J. Thromb. Haemost. 6(5) , 837-45, (2008)

Novel pentapeptides called Thrombostatin FM compounds consisting mostly of D-isomers and unusual amino acids were prepared based upon the stable angiotensin converting enzyme breakdown product of brad...

更多文献